Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated…

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2013

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,610 followers.

@chasingthealpha @TomSilver39 There were some very early data of T-Vec + Yervoy combo at #SITC13 -> http://t.co/ozRaR97GuE

$AMGN $BMY Ph1 of T-vec / Yervoy , 2 PRs, updated data at meeting - http://t.co/qKSYrJ0L2N

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.